vimarsana.com
Home
Live Updates
STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024 : vimarsana.com
STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024
STC-15 is the first METTL3 inhibitor to enter clinical development Clinical data will include safety, pharmacology, target modulation, and clinical activity CAMBRIDGE, England, May
Related Keywords
United States
,
San Antonio
,
Texas
,
Chicago
,
Illinois
,
Cambridge
,
Cambridgeshire
,
United Kingdom
,
American
,
Justin Moser
,
Jordi Rodon Ahnert
,
Kyriakos Papadopoulos
,
Josefin Beate Holz
,
Honorhealth Research Institute
,
American Society Of Clinical Oncology
,
Therapeutics Ltd
,
Storm Therapeutics Ltd
,
Ip Group
,
Utokyo Innovation Platform Co Ltd
,
Fast Track Initiative
,
Justin Moser At Honorhealth Research Institute
,
Seroba Life Sciences
,
Cambridge Innovation Capital
,
University Of Texas Md Anderson Cancer Center
,
Taiho Ventures
,
American Society
,
Clinical Oncology
,
Annual Meeting
,
Cohort Expansion Study Evaluating Safety
,
Clinical Activity
,
Advanced Malignancies
,
Honorhealth Research
,
Jordi Rodon
,
Health Research Institute
,
Cancer Center
,
Saturday June
,
Board Number
,
Presentation Number
,
Pfizer Ventures
,
Cambridge Innovation Capital Limited
,
Ihr Portfolio
,
vimarsana.com © 2020. All Rights Reserved.